Understanding this mechanism of resistance may also suggest ways to release specific sequestered BH3-proteins from Bcl-XL and Bcl-2 to kill cancer cells more selectively than broadly inhibiting anti-apoptotic proteins (Goldsmith et al., 2006; Ni Chonghaile and Letai, 2008). Here, BCL2L1 is linked to cancer.